Raz, Itamar
Cahn, Avivit
Article History
First Online: 10 March 2016
Competing interests
: I.R. declares that he is an Advisory Board member for AstraZeneca/Bristol–Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Labstyle Innovations, Merck, Novo Nordisk, Orgenesis, Sanofi, and SmartZyme Innovation; that he is a consultant for AstraZeneca/Bristol–Meyers Squibb, the Diabetes Medical Center (Tel Aviv, Israel), FuturRx, Insuline Medical, Gili Medical, Kamada, and Nephrogenex; that he is in the Speaker's Bureau of AstraZeneca/Bristol–Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Sanofi, and Teva; and that he is a stock/shareholder of Glucome, Insuline Medical, Labstyle Innovations, Orgenesis, and SmartZyme Innovation. A.C. declares that she has received consulting fees and payment for lectures from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Novo Nordisk, and Sanofi.